BSc, MSc, PhD

Olivier is a highly experienced leader in drug development, biopharmaceuticals, biotechnology and diagnostics. He serves as Chief Scientific Officer – Inflammation at Noxopharm Ltd, and as Chief Scientific Officer for Pharmorage Pty Ltd.

His skillset includes immunoassays, patents, scientific writing and grants, as well as people and project management. Olivier brings to Pharmorage diverse experience in generating both intellectual property and research funding, along with managing effective collaborations with commercial organisations, academic institutions, governments, and private entities at the international level.

Prior to joining Noxopharm, Olivier was a senior research scientist with 3M, PriME Biologics and AEGROS Innovations. He also has had international academic experience with UTS Sydney, Macquarie University, and the Institute of Microelectronics of Barcelona.

Olivier holds a PhD in Biotechnology from the Autonomous University of Barcelona, a Master of Applied Biotechnology and Microbiology from Ecole Supérieure d’Ingénieur de Luminy in Marseille, and a Bachelor degree in Biology and Environmental Sciences from the Institut Universitaire de Technology in Nantes.

MEng (Biol), PhD.

Professor Michael Gantier leads the Nucleic Acids and Innate Immunity laboratory at the Hudson Institute of Medical Research. With over 20 years of expertise in RNA biology, his work focuses on harnessing RNA to modulate innate immune responses for therapeutic benefit.

Trained as a biological engineer in France, he completed his PhD at University College Dublin before moving to Australia to work with Prof Bryan Williams on RNA therapeutics and innate immunity.

Since establishing his independent laboratory in 2015, Prof Gantier’s team has uncovered fundamental immunosuppressive mechanisms of RNA therapeutics, culminating in the discovery that RNA cleavage products mimic natural immune checkpoints against autoimmunity (Alharbi et al., Nature Immunology 2026).

In collaboration with Noxopharm, his group has developed a novel class of ultra short RNA based anti-inflammatory agents that have recently completed Phase 1 clinical trials (Sapkota et al. bioRxiv 2026).

Prof Gantier has received multiple international awards, published extensively in leading journals with over 85 publications to date (including Nature, Cell, Nature Immunology, Nature Communications, Nucleic Acids Research etc), and currently serves as Associate Editor of Molecular Therapy Nucleic Acids.

CA, BBus, GIA(Cert)

Cameron is the Managing Director of Bio101, a financial services firm providing accounting, tax and company secretarial services specialising in the healthcare and life science sectors.

A qualified Chartered Accountant and registered tax agent, Cameron acts as CFO and Company Secretary for a number of ASX listed and Venture Capital investee companies. He has assisted multiple companies through the Initial Public Offering (IPO) process, capital raisings and M&A transactions.

Cameron is a Director and Treasurer of registered charity Cystic Fibrosis Community Care Ltd (CFCC) and Chair of the Investment Committee for CFCC.

BSc Hons; PhD

Mary has built her career in medical science research in world-leading organisations, including Boston Children’s Hospital / Harvard Medical School, Monash University and Hudson Institute of Medical Research.

Her background is in programmed cell death and she has highly relevant experience in infectious and inflammatory disease. She joined Noxopharm in 2021 as a Senior Research Scientist, where she leads the Noxopharm / Pharmorage in vivo research related to autoimmune diseases and mRNA vaccines.

Mary maintains a position at Hudson Institute as an Honorary Research Associate with the Cell Death and Inflammatory Signalling group. She works closely with Associate Professor Michael Gantier’s team there and acts as a valuable link between Hudson Institute and Noxopharm / Pharmorage. Her work contributes to the scientific progress being made in the development and discovery of new anti-inflammatory drugs for a range of diseases.

Mary has a PhD from Monash University and a Bachelor of Science with Honours (1st class) from the University of Otago (Te Whare Wānanga o Otāgo).

BSc Hons; PhD.

Daniel is a pharmaceutical chemist with a broad background across academic and pharmaceutical industry roles.

His experience includes environmental science and, more recently, drug discovery. Working for UNSW and in commercial drug development, Daniel has developed technical expertise and skill in both the design and synthesis of small molecules.

Daniel joined Noxopharm in 2020 and is Director of Pharmaceutical Chemistry, taking responsibility for Noxopharm and Pharmorage projects. In this position he has driven the pharmaceutical chemistry efforts on multiple projects and oversees every aspect of the drug discovery process alongside the biology-focused Noxopharm team members.

Daniel’s expertise has been recognised with his recent appointment as Visiting Fellow at UNSW Sydney. This position maintains his close links with UNSW Sydney and allows for further collaboration between Noxopharm / Pharmorage and the University.

Daniel holds a PhD in Medicinal Chemistry from UNSW Sydney, funded by a UNSW Research Excellence Award, and a Bachelor of Science from University of Technology Sydney.